Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

J. Paavonen; D. Jenkins; X.F. Bosch; P.D. Naud; J. Salmeron; C.M. Wheeler; S. Chow; D.L. Apter; H.C. Kitchener; X. Castellsague; N. S De Carvalho; Susan Skinner

doi:10.1016/S0140-6736(07)60946-5

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

J. Paavonen
, D. Jenkins
, X.F. Bosch
, P.D. Naud
, J. Salmeron
, C.M. Wheeler
, S. Chow
, D.L. Apter
, H.C. Kitchener
, X. Castellsague
, N. S De Carvalho
, Susan Skinner

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	2161-70
Journal	The Lancet
Volume	369
Issue number	9580
DOIs	https://doi.org/10.1016/S0140-6736(07)60946-5
Publication status	Published - 2007

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/S0140-6736(07)60946-5

Cite this

Paavonen, J., Jenkins, D., Bosch, X. F., Naud, P. D., Salmeron, J., Wheeler, C. M., Chow, S., Apter, D. L., Kitchener, H. C., Castellsague, X., S De Carvalho, N., & Skinner, S. (2007). Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet, 369(9580), 2161-70. https://doi.org/10.1016/S0140-6736(07)60946-5

@article{9160ef65251a476aadf4f7a2946acace,

title = "Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial",

author = "J. Paavonen and D. Jenkins and X.F. Bosch and P.D. Naud and J. Salmeron and C.M. Wheeler and S. Chow and D.L. Apter and H.C. Kitchener and X. Castellsague and \{S De Carvalho\}, N. and Susan Skinner",

year = "2007",

doi = "10.1016/S0140-6736(07)60946-5",

language = "English",

volume = "369",

pages = "2161--70",

journal = "The Lancet",

issn = "0140-6736",

publisher = "Elsevier",

number = "9580",

}

Paavonen, J, Jenkins, D, Bosch, XF, Naud, PD, Salmeron, J, Wheeler, CM, Chow, S, Apter, DL, Kitchener, HC, Castellsague, X, S De Carvalho, N & Skinner, S 2007, 'Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial', The Lancet, vol. 369, no. 9580, pp. 2161-70. https://doi.org/10.1016/S0140-6736(07)60946-5

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. / Paavonen, J.; Jenkins, D.; Bosch, X.F. et al.
In: The Lancet, Vol. 369, No. 9580, 2007, p. 2161-70.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

AU - Paavonen, J.

AU - Jenkins, D.

AU - Bosch, X.F.

AU - Naud, P.D.

AU - Salmeron, J.

AU - Wheeler, C.M.

AU - Chow, S.

AU - Apter, D.L.

AU - Kitchener, H.C.

AU - Castellsague, X.

AU - S De Carvalho, N.

AU - Skinner, Susan

PY - 2007

Y1 - 2007

U2 - 10.1016/S0140-6736(07)60946-5

DO - 10.1016/S0140-6736(07)60946-5

M3 - Article

SN - 0140-6736

VL - 369

SP - 2161

EP - 2170

JO - The Lancet

JF - The Lancet

IS - 9580

ER -

Paavonen J, Jenkins D, Bosch XF, Naud PD, Salmeron J, Wheeler CM et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. The Lancet. 2007;369(9580):2161-70. doi: 10.1016/S0140-6736(07)60946-5